Project Description
Based on the fundamental principles and technology of synthetic biology, our
team aims at designing a new immune system containing transdermal peptide that
expresses genes and produces immune responses simultaneously. To reach this
goal, we need to build four kinds of engineered bacteria and find out
effective immune responses. Meanwhile, an appropriate reporting system guiding
vaccination at different stages is also required to meet the demand of
practical, safe and human-friendly production. The Bacillus subtilis we use is
WB800N, which is modified into four types of engineered bacteria, combined
with the gene coding LTB, HBsAg, reporter, and LC Luman-recruiting factor
respectively, each of which contains the gene coding transdermal peptide.
Then, the engineered bacteria will produce mixture of fusion protein in the
skin and activate immune responses.
The introducing of transdermal peptide, together with the simultaneous immune
response with protein expression, has granted our work great advantages over
other existing immune system, both in economy and operation. Therefore it is
expected to become a promising new vaccine research field.
So far, we have successfully synthesize four kinds of plasmids, and the
sequences of them all have been proved correct. Additionally, we have managed
to transform three plasmids from E. coli to Bacillus subtilis, leaving GFP in
progress.
For the coming days, we plan to continue our transformation and experiment on
the mice to check the effects of our vaccine, whereas other tasks, such as
human practice and the standardization of our parts, are in our future
schedule.
Project
Description
Based on the fundamental principles and technology of synthetic biology, our
team aims at designing a new immune system containing transdermal peptide that
expresses genes and produces immune responses simultaneously. To reach this
goal, we need to build four kinds of engineered bacteria and find out
effective immune responses. Meanwhile, an appropriate reporting system guiding
vaccination at different stages is also required to meet the demand of
practical, safe and human-friendly production. The Bacillus subtilis we use is
WB800N, which is modified into four types of engineered bacteria, combined
with the gene coding LTB, HBsAg, reporter, and LC Luman-recruiting factor
respectively, each of which contains the gene coding transdermal peptide.
Then, the engineered bacteria will produce mixture of fusion protein in the
skin and activate immune responses.
The introducing of transdermal peptide, together with the simultaneous immune
response with protein expression, has granted our work great advantages over
other existing immune system, both in economy and operation. Therefore it is
expected to become a promising new vaccine research field.
So far, we have successfully synthesize four kinds of plasmids, and the
sequences of them all have been proved correct. Additionally, we have managed
to transform three plasmids from E. coli to Bacillus subtilis, leaving GFP in
progress.
For the coming days, we plan to continue our transformation and experiment on
the mice to check the effects of our vaccine, whereas other tasks, such as
human practice and the standardization of our parts, are in our future
schedule.
Project
Description
Based on the fundamental principles and technology of synthetic biology, our
team aims at designing a new immune system containing transdermal peptide that
expresses genes and produces immune responses simultaneously. To reach this
goal, we need to build four kinds of engineered bacteria and find out
effective immune responses. Meanwhile, an appropriate reporting system guiding
vaccination at different stages is also required to meet the demand of
practical, safe and human-friendly production. The Bacillus subtilis we use is
WB800N, which is modified into four types of engineered bacteria, combined
with the gene coding LTB, HBsAg, reporter, and LC Luman-recruiting factor
respectively, each of which contains the gene coding transdermal peptide.
Then, the engineered bacteria will produce mixture of fusion protein in the
skin and activate immune responses.
The introducing of transdermal peptide, together with the simultaneous immune
response with protein expression, has granted our work great advantages over
other existing immune system, both in economy and operation. Therefore it is
expected to become a promising new vaccine research field.
So far, we have successfully synthesize four kinds of plasmids, and the
sequences of them all have been proved correct. Additionally, we have managed
to transform three plasmids from E. coli to Bacillus subtilis, leaving GFP in
progress.
For the coming days, we plan to continue our transformation and experiment on
the mice to check the effects of our vaccine, whereas other tasks, such as
human practice and the standardization of our parts, are in our future
schedule.
Project
Description
Based on the fundamental principles and technology of synthetic biology, our
team aims at designing a new immune system containing transdermal peptide that
expresses genes and produces immune responses simultaneously. To reach this
goal, we need to build four kinds of engineered bacteria and find out
effective immune responses. Meanwhile, an appropriate reporting system guiding
vaccination at different stages is also required to meet the demand of
practical, safe and human-friendly production. The Bacillus subtilis we use is
WB800N, which is modified into four types of engineered bacteria, combined
with the gene coding LTB, HBsAg, reporter, and LC Luman-recruiting factor
respectively, each of which contains the gene coding transdermal peptide.
Then, the engineered bacteria will produce mixture of fusion protein in the
skin and activate immune responses.
The introducing of transdermal peptide, together with the simultaneous immune
response with protein expression, has granted our work great advantages over
other existing immune system, both in economy and operation. Therefore it is
expected to become a promising new vaccine research field.
So far, we have successfully synthesize four kinds of plasmids, and the
sequences of them all have been proved correct. Additionally, we have managed
to transform three plasmids from E. coli to Bacillus subtilis, leaving GFP in
progress.
For the coming days, we plan to continue our transformation and experiment on
the mice to check the effects of our vaccine, whereas other tasks, such as
human practice and the standardization of our parts, are in our future
schedule.